Related Experiment Videos
[Pharmacokinetic studies on micronomicin in rats. Comparison of intramuscular and drip intravenous administration
Abstract:
Absorption, tissue distribution and excretion of micronomicin (MCR) were studied in rats after intramuscular or 30 minutes drip intravenous administration (10 mg/kg). Serum levels of MCR were measured by bioassay, enzyme immunoassay and high pressure liquid chromatography. The pharmacokinetic studies of MCR after intramuscular or drip intravenous administration were carried out using one-compartment open model or two-compartment open model, respectively. Among 3 assay methods, similar pharmacokinetic parameters of MCR were obtained. In the simulation of serum levels of MCR, the differences between the measured and calculated serum levels after intramuscular or drip intravenous administration were less than 19% of the former levels. After intramuscular or drip intravenous administration of MCR, similar changes of the organ (kidneys, lungs, spleen and liver) levels were observed. Urinary recovery rates of MCR amounted to 82.3% or 91.6% by 24 hours after intramuscular or drip intravenous administration, respectively. After intramuscular or drip intravenous administration of MCR, no metabolites were found in urine of rats.
Insights
Micronomicin (MCR) absorption, distribution, and excretion were studied in rats. Pharmacokinetic parameters were consistent across three assay methods and administration routes, with high urinary recovery and no detected metabolites.
Area of Science:
- Pharmacology
- Drug Metabolism
- Toxicology
Background:
- Micronomicin (MCR) is an aminoglycoside antibiotic.
- Understanding MCR's pharmacokinetic profile is crucial for optimizing therapeutic use and safety.
Purpose of the Study:
- To investigate the absorption, tissue distribution, and excretion of micronomicin (MCR) in rats.
- To compare pharmacokinetic parameters obtained using bioassay, enzyme immunoassay, and high-pressure liquid chromatography.
- To evaluate MCR's behavior following intramuscular and intravenous administration.
Main Methods:
- Rats were administered MCR (10 mg/kg) via intramuscular or 30-minute drip intravenous routes.
- Serum MCR levels were quantified using bioassay, enzyme immunoassay, and HPLC.
- Pharmacokinetic analysis employed one-compartment and two-compartment open models.
- Organ distribution and urinary excretion were assessed.
Main Results:
- Consistent pharmacokinetic parameters were observed across the three analytical methods.
- Simulated serum MCR levels closely matched measured levels (within 19% difference).
- Similar organ-level changes (kidneys, lungs, spleen, liver) were noted post-administration.
- Urinary recovery rates were high: 82.3% (intramuscular) and 91.6% (intravenous) within 24 hours.
- No MCR metabolites were detected in rat urine.
Conclusions:
- The pharmacokinetic profile of MCR is predictable and consistent across different administration routes and analytical methods.
- High urinary excretion suggests efficient elimination of MCR.
- The absence of metabolites indicates minimal biotransformation in rats.